Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lifitegrast
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Novartis intends to develop the AcuStream technology for potential use with its existing and future front-of-eye therapies, which could include Xiidra® (lifitegrast ophthalmic solution) 5%, a first-in-class prescription LFA 1 antagonist for the treatmen...
Product Name : Xiidra
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 30, 2022
Lead Product(s) : Lifitegrast
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
